Medtech-Aktien nach dem Reset: Stryker, Intuitive Surgical, ResMed & Co. im Check
1 extracted signal · 0 resolved · 1 still active
onvistaIndependent analyst profile- Source published
- 29 Sept 2026, 12:00 UTC
- Recorded by Tahlil Plus
- 29 Sept 2026, 12:25 UTC
AI-generated source summary
The analysis covers two stocks, SYK and ISRG, using weekly chart technical analysis. For SYK, the stock is observed to be in a downtrend, having broken below key support levels and moving averages, including the 50-week and 200-week MAs. The current price is near a significant support level around $250, which, if broken, could lead to further downside. However, there's a possibility of a bounce towards the resistance zone around $330-$340. The RSI shows oversold conditions, suggesting a potential short-term bounce, but the overall trend remains bearish until a clear reversal pattern or break above key resistance levels is established. For ISRG, the stock has also experienced a significant downtrend, breaking below its 200-day MA. The current price is near a support level around $340-$357. A potential rebound is observed, with resistance at $396 and $405. The RSI is moving towards oversold territory, suggesting a potential short-term reversal, but the overall trend indicates caution. The analysis highlights the importance of key Fibonacci retracement levels and volume profiles in identifying potential support and resistance zones.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
onvista
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.